Trials / Completed
CompletedNCT00193518
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL
Detailed description
Upon determination of eligibility, patients will receive: * Arsenic Trioxide
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arsenic Trioxide |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2005-09-19
- Last updated
- 2011-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00193518. Inclusion in this directory is not an endorsement.